Sun Pharmaceutical Industries Ltd (SUNPHARMA):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9947)
◆英語タイトル:Sun Pharmaceutical Industries Ltd (SUNPHARMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9947
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:120
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Sun Pharmaceutical Industries Ltd (Sun Pharma) is a specialty pharmaceutical company, which offers a wide range of pharmaceutical formulations such as branded generics and generic pharmaceuticals. The company’s products find application in the treatment of various conditions related to psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopedics and ophthalmology. The company carries out product development, process chemistry, and manufacture of complex active pharmaceutical ingredients (APIs), over-the-counter products and formulations. It offers drugs in various dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams and liquids. The company has manufacturing facilities in North America, Latin America, EMEA and Asia Pacific. Sun Pharma is headquartered in Mumbai, Maharashtra, India.

Sun Pharmaceutical Industries Ltd (SUNPHARMA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sun Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Sun Pharma to Acquire Odomzo from Novartis 19
Sun Pharma Acquires 14 Brands from Novartis for USD293 Million 20
Sun Pharma Acquires Opiates Business in Australia from GlaxoSmithKline 21
Sun Pharma Plans To Acquire Injectable And Oral Business 22
InSite Vision Regains North American Development Rights To AzaSite Xtra From Inspire Pharma 23
Venture Financing 24
scPharma Raises USD45.6 Million in Series B Financing 24
Partnerships 26
Sun Pharma Enters into Agreement with National Institute of Virology 26
Sun Pharma Enters into Agreement with International Centre for Genetic Engineering and Biotechnology 27
Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 28
Sun Pharma Enters into Co-Development Agreement with International Centre for Genetic Engineering and Biotechnology 29
ICGEB Enters into Partnership with Sun Pharma 30
Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 31
Sun Pharma Enters into Research Agreement with Weizmann Institute of Science and Health Research Institute of Santiago de Compostela 32
Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 33
Mapi Pharma Enters into Agreement with Taro Pharma 34
Sun Pharma Forms Joint Venture With Intrexon To Develop Therapeutics For Ocular Diseases 35
Daiichi Sankyo Enters Into Co-Marketing Agreement With Terapia Ranbaxy For Sevikar 36
Licensing Agreements 37
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 37
Sun Pharma Enters into Licensing Agreement with Moebius Medical 38
Sun Pharma Enters into Licensing Agreement with SPARC 39
Sun Pharma Enters into Licensing Agreement with Technion to Develop Anti-Cancer Drugs 40
InSite Vision Enters into Licensing Agreement with Nicox for AzaSite, AzaSite Xtr and BromSite 41
Sun Pharma Enters into Licensing Agreement with Merck 42
Gilead Sciences Expands Licensing Agreement with Sun Pharma 43
InSite Vision Enters into Licensing Agreement with Senju Pharma for Azithromycin Ophthalmic Solution 44
Suven Life Science Enters Into Licensing Agreement With Taro Pharma To Market Malathion Lotion 45
Almirall Enters into Licensing Agreement with Sun Pharma for Tildrakizumab 46
Sun Pharma Advanced Research Enters Into Licensing Agreement With Sun Pharma 47
Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 48
InSite Vision Amends Licensing Agreement With Inspire Pharma For AzaSite 49
Equity Offering 50
Sun Pharma Advanced Plans to Raise Additional Funds in Rights Offering of Shares 50
Sun Pharma Advanced Research Company to Raise USD39 Million in Rights Offering of Shares 51
Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 52
Sun Pharma Plans to Raise USD1.97 Billion in Private Placement of Securities 53
Sun Pharma Plans To Raise US$1.5 Billion In Public Offering Of Shares 54
Sun Pharma Advanced Research Completes Rights Issue Of Shares For US$36 Million 55
Debt Offering 57
Sun Pharma Plans to Raise USD1.8 Billion in Private Placement of Debentures 57
Asset Transactions 58
RPG Life Sciences Acquires 7 Prescription Drug Brands from Sun Pharma for USD6 Million 58
Frontida BioPharm Acquires Two Manufacturing Units of Sun Pharma 59
Nostrum Labs to Acquire Manufacturing Unit in Ohio from Sun Pharma 60
Strides Arcolab to Acquire Ranbaxy’s CNS Business from Sun Pharma for USD25 Million 61
Sun Pharma Plans to Divest Ranbaxy’s Ireland Manufacturing Plant 62
Tribute Pharma Acquires US Rights to Fibricor for USD10 Million 63
Emcure Pharma to Acquire Seven Drugs from Sun Pharma and Ranbaxy Labs 64
InSite Vision Sells Royalty Of Besivance To SWK Funding And Bess Royalty For US$16 Million 65
Acquisition 66
Sun Pharma to Acquire 18.75% Stake in Tarsius Pharma for USD3 Million 66
Sun Pharma Acquires Additional 6.35% Stake in Ranbaxy Malaysia for USD0.6 Million 67
Sun Pharma to Acquire 8.3% Stake in Ranbaxy Malaysia 68
Sun Pharma Acquires 15.91% Stake in Krystal Biotech 69
Taro Pharma To Acquire Thallion Pharma for USD2 Million 70
Sun Pharma Acquires 14.58% Stake in scPharma for USD13 Million 71
Sun Pharma Acquires 85.1% Stake in Biosintez for up to USD60 million 72
Sun Pharma Acquires Ocular Technologies from Auven Therapeutics 73
Sun Pharma May Acquire Controlling Stake in Martindale Pharma 74
Sun Pharma Acquires InSite Vision 75
Taro Pharma Acquires Zalicus Pharma 77
Sun Pharma Acquires Ranbaxy Labs for USD4 Billion 78
Sun Pharma Acquires Pharmalucence, Provider of Injectable Pharma Products 81
Sun Pharma To Acquire 28.1% Stake In Zenotech Labs For US$3 Million 82
Sun Pharmaceutical Industries Plans To Acquire Companies In Japan 83
Sun Pharma Completes Acquisition Of Dusa Pharma For US$230 Million 84
Sun Pharma Plans To Acquire Generic Companies 86
Sun Pharma Mulls Acquisition Of Stada Arzneimittel 87
Sun Pharmaceutical Industries Ltd – Key Competitors 88
Sun Pharmaceutical Industries Ltd – Key Employees 89
Sun Pharmaceutical Industries Ltd – Locations And Subsidiaries 90
Head Office 90
Other Locations & Subsidiaries 90
Joint Venture 97
Recent Developments 98
Financial Announcements 98
Aug 14, 2018: Sun Pharma reports Q1FY19 results 98
May 25, 2018: Sun Pharma reports Q4 & FY18 results 100
Feb 14, 2018: Sun Pharma reports Q3FY18 results 102
Nov 14, 2017: Sun Pharma reports Q2FY18 results 104
Aug 11, 2017: Sun Pharma reports Q1FY18 results 106
May 26, 2017: Sun Pharma reports Q4 & FY17 results 108
Feb 14, 2017: Sun Pharma reports Q3FY17 results 110
Corporate Communications 112
Mar 23, 2018: FDEC First Year Report of Malaria Elimination Demonstration Project (MEDP) 112
Jul 12, 2017: Sun Pharmaceutical Industries Announces Appointment of Mr. Kalyansundaram Subramanian as the Director 113
Legal and Regulatory 114
Jun 12, 2018: Sun Pharma receives EIR for Halol facility 114
Feb 23, 2018: Sun Pharmaceutical Industries: Update on US FDA Halol Inspection 115
Jul 07, 2017: SUN Pharma: Intimation of settlement in re Modajmnil Antitrust Litigation matter 116
Mar 14, 2017: Sun Pharma Provides Update on Mohali Facility 117
Mar 14, 2017: Sun Pharmaceutical Industries Provides Update on Mohali Facility 118
Product News 119
Aug 29, 2018: Sun Pharma launches Volini Maxx, India’s Strongest Pain Relief Spray 119
Appendix 120
Methodology 120
About GlobalData 120
Contact Us 120
Disclaimer 120

List of Tables
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sun Pharmaceutical Industries Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Sun Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Sun Pharma to Acquire Odomzo from Novartis 19
Sun Pharma Acquires 14 Brands from Novartis for USD293 Million 20
Sun Pharma Acquires Opiates Business in Australia from GlaxoSmithKline 21
Sun Pharma Plans To Acquire Injectable And Oral Business 22
InSite Vision Regains North American Development Rights To AzaSite Xtra From Inspire Pharma 23
scPharma Raises USD45.6 Million in Series B Financing 24
Sun Pharma Enters into Agreement with National Institute of Virology 26
Sun Pharma Enters into Agreement with International Centre for Genetic Engineering and Biotechnology 27
Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 28
Sun Pharma Enters into Co-Development Agreement with International Centre for Genetic Engineering and Biotechnology 29
ICGEB Enters into Partnership with Sun Pharma 30
Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 31
Sun Pharma Enters into Research Agreement with Weizmann Institute of Science and Health Research Institute of Santiago de Compostela 32
Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 33
Mapi Pharma Enters into Agreement with Taro Pharma 34
Sun Pharma Forms Joint Venture With Intrexon To Develop Therapeutics For Ocular Diseases 35
Daiichi Sankyo Enters Into Co-Marketing Agreement With Terapia Ranbaxy For Sevikar 36
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 37
Sun Pharma Enters into Licensing Agreement with Moebius Medical 38
Sun Pharma Enters into Licensing Agreement with SPARC 39
Sun Pharma Enters into Licensing Agreement with Technion to Develop Anti-Cancer Drugs 40
InSite Vision Enters into Licensing Agreement with Nicox for AzaSite, AzaSite Xtr and BromSite 41
Sun Pharma Enters into Licensing Agreement with Merck 42
Gilead Sciences Expands Licensing Agreement with Sun Pharma 43
InSite Vision Enters into Licensing Agreement with Senju Pharma for Azithromycin Ophthalmic Solution 44
Suven Life Science Enters Into Licensing Agreement With Taro Pharma To Market Malathion Lotion 45
Almirall Enters into Licensing Agreement with Sun Pharma for Tildrakizumab 46
Sun Pharma Advanced Research Enters Into Licensing Agreement With Sun Pharma 47
Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 48
InSite Vision Amends Licensing Agreement With Inspire Pharma For AzaSite 49
Sun Pharma Advanced Plans to Raise Additional Funds in Rights Offering of Shares 50
Sun Pharma Advanced Research Company to Raise USD39 Million in Rights Offering of Shares 51
Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 52
Sun Pharma Plans to Raise USD1.97 Billion in Private Placement of Securities 53
Sun Pharma Plans To Raise US$1.5 Billion In Public Offering Of Shares 54
Sun Pharma Advanced Research Completes Rights Issue Of Shares For US$36 Million 55
Sun Pharma Plans to Raise USD1.8 Billion in Private Placement of Debentures 57
RPG Life Sciences Acquires 7 Prescription Drug Brands from Sun Pharma for USD6 Million 58
Frontida BioPharm Acquires Two Manufacturing Units of Sun Pharma 59
Nostrum Labs to Acquire Manufacturing Unit in Ohio from Sun Pharma 60
Strides Arcolab to Acquire Ranbaxy's CNS Business from Sun Pharma for USD25 Million 61
Sun Pharma Plans to Divest Ranbaxy’s Ireland Manufacturing Plant 62
Tribute Pharma Acquires US Rights to Fibricor for USD10 Million 63
Emcure Pharma to Acquire Seven Drugs from Sun Pharma and Ranbaxy Labs 64
InSite Vision Sells Royalty Of Besivance To SWK Funding And Bess Royalty For US$16 Million 65
Sun Pharma to Acquire 18.75% Stake in Tarsius Pharma for USD3 Million 66
Sun Pharma Acquires Additional 6.35% Stake in Ranbaxy Malaysia for USD0.6 Million 67
Sun Pharma to Acquire 8.3% Stake in Ranbaxy Malaysia 68
Sun Pharma Acquires 15.91% Stake in Krystal Biotech 69
Taro Pharma To Acquire Thallion Pharma for USD2 Million 70
Sun Pharma Acquires 14.58% Stake in scPharma for USD13 Million 71
Sun Pharma Acquires 85.1% Stake in Biosintez for up to USD60 million 72
Sun Pharma Acquires Ocular Technologies from Auven Therapeutics 73
Sun Pharma May Acquire Controlling Stake in Martindale Pharma 74
Sun Pharma Acquires InSite Vision 75
Taro Pharma Acquires Zalicus Pharma 77
Sun Pharma Acquires Ranbaxy Labs for USD4 Billion 78
Sun Pharma Acquires Pharmalucence, Provider of Injectable Pharma Products 81
Sun Pharma To Acquire 28.1% Stake In Zenotech Labs For US$3 Million 82
Sun Pharmaceutical Industries Plans To Acquire Companies In Japan 83
Sun Pharma Completes Acquisition Of Dusa Pharma For US$230 Million 84
Sun Pharma Plans To Acquire Generic Companies 86
Sun Pharma Mulls Acquisition Of Stada Arzneimittel 87
Sun Pharmaceutical Industries Ltd, Key Competitors 88
Sun Pharmaceutical Industries Ltd, Key Employees 89
Sun Pharmaceutical Industries Ltd, Subsidiaries 90
Sun Pharmaceutical Industries Ltd, Joint Venture 97

List of Figures
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sun Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 13

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Sun Pharmaceutical Industries Ltd (SUNPHARMA):製薬・医療:M&Aディール及び事業提携情報(Sun Pharmaceutical Industries Ltd (SUNPHARMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆